Unraveling the Length of Hospital Stay for Patients with Urinary Tract Infections: Contributing Factors and Microbial Susceptibility
Antibiotics · 21.04.2025 · 14 (4) · 421
DOI: 10.3390/antibiotics14040421 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antibiotics, online erschienen am 21.04.2025. Verfasst von Deema Rahme und 2 weiteren Autor:innen. Beteiligte Einrichtung: Ecole Doctorale des Sciences et des Technologies, Lebanese University, Hadat P.O. Box 6573/14, Lebanon. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Length of hospital stay (LOS) is a critical measure of healthcare efficiency. This study investigated factors contributing to prolonged LOS in adult patients with urinary tract infections (UTIs) in Lebanon and assessed microbial susceptibility patterns of causative pathogens.
Methods
A retrospective cohort study was conducted across five Lebanese university hospitals (March 2022–December 2023), analyzing 401 patients. Data on microbiological findings and the LOS were extracted from medical records. Statistical analyses, including descriptive statistics, bivariate tests (t-tests, ANOVA, and Pearson’s correlation), and multiple linear regression (significance: p ≤ 0.05), were performed using IBM SPSS® 27.
Results
The mean LOS was 5.85 ± 2.41 days. Prolonged hospitalization was associated with patient-related factors (age, comorbidities, UTI type, specific symptoms, and multidrug-resistant infections) and treatment-related factors. Empirical use of carbapenems (β = 0.783, p = 0.004) and fluoroquinolones (β = 1.360, p = 0.014), along with inappropriate antibiotic prescriptions (β = 0.609, p = 0.022), significantly extended the LOS. Conversely, antibiotic de-escalation based on culture results reduced the LOS (β = −0.567, p = 0.029). Escherichia coli (61.8%) was the predominant pathogen, followed by Klebsiella pneumoniae (11.9%), Proteus mirabilis (7.8%), and Pseudomonas aeruginosa (7.5%). Notably, susceptibility to antibiotics showed a concerning decline.
Conclusions
Inappropriate antibiotic prescriptions were linked to a prolonged LOS, emphasizing the need for judicious antimicrobial use. The positive impact of de-escalation supports culture-guided therapy. Declining antibiotic susceptibility highlights the urgency for robust antimicrobial stewardship programs (ASPs) and a national microbial resistance database to combat antimicrobial resistance (AMR) in Lebanon.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Ecole Doctorale des Sciences et des Technologies, Lebanese University, Hadat P.O. Box 6573/14, Lebanon.
- Faculty of Pharmacy, Beirut Arab University, Beirut P.O. Box 11-5020, Lebanon.
- INSPECT-LB (Institut National de Santé Publique, d'Épidémiologie Clinique et de Toxicologie-Liban), Beirut P.O. Box 12109, Lebanon.
- Gilbert and Rose-Marie Chagoury School of Medicine, Lebanese American University, Byblos P.O. Box 36, Lebanon.
- Department of Primary Care and Population Health, University of Nicosia Medical School, 2417 Nicosia, Cyprus.
ORCID-Profile: Deema Rahme, Pascale Salameh
Zitieren
APA
Rahme, D., Nakkash Chmaisse, H., & Salameh, P. (2025). Unraveling the Length of Hospital Stay for Patients with Urinary Tract Infections: Contributing Factors and Microbial Susceptibility. Antibiotics, 14(4), 421. https://doi.org/10.3390/antibiotics14040421
Vancouver
Rahme D, Nakkash Chmaisse H, Salameh P. Unraveling the Length of Hospital Stay for Patients with Urinary Tract Infections: Contributing Factors and Microbial Susceptibility. Antibiotics. 2025;14(4):421. doi:10.3390/antibiotics14040421
BibTeX
@article{Rahme2025,
author = {Rahme, Deema and Nakkash Chmaisse, Hania and Salameh, Pascale},
title = {Unraveling the Length of Hospital Stay for Patients with Urinary Tract Infections: Contributing Factors and Microbial Susceptibility},
journal = {Antibiotics},
year = {2025},
volume = {14},
number = {4},
pages = {421},
doi = {10.3390/antibiotics14040421}
}
EUVIMED